Unicycive Therapeutics (UNCY) Cash & Equivalents (2021 - 2026)

Unicycive Therapeutics (UNCY) has 6 years of Cash & Equivalents data on file, last reported at $37.4 million in Q1 2026.

• Quarterly Cash & Equivalents rose 89.04% year-over-year to $37.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $37.4 million (up 89.04% YoY) and the FY2025 annual result came in at $29.2 million, up 11.69% from the prior year.
• Cash & Equivalents climbed to $37.4 million in Q1 2026, from $29.2 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $48.9 million in Q1 2024 to a low of $455000.0 in Q4 2022.
• A 5-year average of $23.5 million and a median of $22.3 million in 2025 frame the typical range for Cash & Equivalents.
• The widest YoY moves for Cash & Equivalents: up 1057200.0% in 2022, down 97.26% in 2022.
• Tracing UNCY's Cash & Equivalents over 5 years: stood at $455000.0 in 2022, then surged by 2032.09% to $9.7 million in 2023, then jumped by 169.48% to $26.1 million in 2024, then rose by 11.69% to $29.2 million in 2025, then advanced by 27.99% to $37.4 million in 2026.
• The last three Cash & Equivalents figures came in at $37.4 million (Q1 2026), $29.2 million (Q4 2025), and $42.7 million (Q3 2025), per Business Quant data.